Jinhe Biotechnology Financials
| 002688 Stock | 4.77 0.11 2.36% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 167.7 M | 215.9 M |
|
|
Jinhe | Select Account or Indicator |
Understanding current and past Jinhe Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jinhe Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Jinhe Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of Jinhe Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jinhe Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jinhe Biotechnology's management manipulating its earnings.
Jinhe Biotechnology Stock Summary
Jinhe Biotechnology competes with Rising Nonferrous, Shandong Polymer, North Copper, Marssenger Kitchenware, and Zijin Mining. Jinhe Biotechnology is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE100001HK7 |
| Business Address | 1-7-2 Building 27, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.jinhe.com.cn |
You should never invest in Jinhe Biotechnology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Jinhe Stock, because this is throwing your money away. Analyzing the key information contained in Jinhe Biotechnology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Jinhe Biotechnology Key Financial Ratios
Jinhe Biotechnology's financial ratios allow both analysts and investors to convert raw data from Jinhe Biotechnology's financial statements into concise, actionable information that can be used to evaluate the performance of Jinhe Biotechnology over time and compare it to other companies across industries.| Revenue | 2.17 B | ||||
| Gross Profit | 665.68 M | ||||
| EBITDA | 387.55 M | ||||
| Net Income | 86.46 M | ||||
| Total Asset | 5.45 B |
Jinhe Biotechnology Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 3.4B | 4.1B | 4.5B | 5.5B | 6.3B | 6.6B | |
| Other Current Liab | 1.9M | 33.1M | 78.1M | 14.2M | 16.3M | 21.0M | |
| Net Debt | 1.0B | 490.4M | 1.1B | 1.7B | 1.9B | 2.0B | |
| Retained Earnings | 453.0M | 481.1M | 556.3M | 560.1M | 644.1M | 344.1M | |
| Accounts Payable | 97.0M | 122.0M | 263.1M | 254.9M | 293.1M | 307.8M | |
| Cash | 314.8M | 517.7M | 491.4M | 608.1M | 699.4M | 734.3M | |
| Net Receivables | 444.7M | 526.3M | 534.5M | 710.8M | 817.4M | 858.3M | |
| Inventory | 447.3M | 577.2M | 675.9M | 670.6M | 771.1M | 809.7M | |
| Other Current Assets | 33.4M | 28.8M | 44.7M | 49.6M | 57.0M | 59.9M | |
| Total Liab | 1.6B | 1.4B | 2.1B | 2.9B | 3.4B | 3.5B | |
| Total Current Assets | 1.2B | 1.6B | 1.7B | 2.0B | 2.3B | 2.5B | |
| Short Term Debt | 1.2B | 921.1M | 1.3B | 1.8B | 2.0B | 2.1B | |
| Intangible Assets | 683.4M | 714.4M | 710.7M | 743.7M | 855.3M | 436.7M | |
| Other Liab | 124.6M | 118.9M | 117.3M | 111.8M | 128.6M | 104.4M | |
| Long Term Debt | 135M | 87M | 296.2M | 497.5M | 572.1M | 600.7M | |
| Good Will | 309.9M | 296.0M | 298.9M | 497.9M | 572.6M | 314.3M | |
| Net Tangible Assets | 677.8M | 679.4M | 1.5B | 1.3B | 1.5B | 897.7M | |
| Short Long Term Debt | 1.1B | 833.9M | 1.2B | 1.7B | 1.9B | 2.0B | |
| Net Invested Capital | 2.9B | 3.4B | 3.8B | 4.4B | 5.1B | 3.5B | |
| Net Working Capital | (132.9M) | 486.3M | 81.9M | (217.7M) | (196.0M) | (186.2M) |
Jinhe Biotechnology Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 60.3M | 56.3M | 46.6M | 9.1M | 10.4M | 20.8M | |
| Total Revenue | 1.8B | 2.1B | 2.1B | 2.2B | 2.5B | 1.5B | |
| Operating Income | 231.3M | 230.9M | 172.0M | 187.7M | 215.9M | 167.7M | |
| Cost Of Revenue | 1.2B | 1.4B | 1.5B | 1.5B | 1.8B | 967.2M | |
| Income Before Tax | 140.9M | 142.9M | 118.8M | 101.5M | 116.7M | 139.9M | |
| Net Income | 117.3M | 94.0M | 75.5M | 86.5M | 99.4M | 111.0M | |
| Income Tax Expense | 29.9M | 1.7M | 20.8M | 804.3K | 924.9K | 878.7K | |
| Minority Interest | 135.1M | (28.1M) | (42.5M) | (8.0M) | (7.2M) | (6.8M) | |
| Research Development | 66.4M | 72.3M | 82.3M | 74.0M | 85.1M | 53.7M | |
| Gross Profit | 629.9M | 651.1M | 613.8M | 642.5M | 738.9M | 638.3M | |
| Ebit | 240.8M | 210.9M | 203.0M | 164.5M | 148.0M | 168.1M | |
| Tax Provision | 1.7M | 20.8M | 804.3K | 7.1M | 6.4M | 6.0M | |
| Net Interest Income | (53.3M) | (56.1M) | (47.6M) | 13.9M | 16.0M | 16.8M | |
| Interest Income | 9.5M | 1.7M | 1.9M | 8.4M | 9.6M | 10.1M | |
| Ebitda | 381.0M | 321.2M | 331.3M | 321.3M | 369.5M | 356.4M |
Jinhe Biotechnology Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Jinhe Biotechnology. It measures of how well Jinhe is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Jinhe Biotechnology brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Jinhe had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Jinhe Biotechnology has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Dividends Paid | 222.9M | 104.3M | 40.5M | 148.7M | 171.0M | 90.5M | |
| Capital Expenditures | 204.0M | 383.7M | 402.2M | 457.2M | 525.8M | 552.1M | |
| Net Income | 117.3M | 94.0M | 75.5M | 86.5M | 99.4M | 110.9M | |
| Change To Inventory | (19.8M) | (135.6M) | (105.6M) | 11.5M | 10.4M | 10.9M | |
| Change In Cash | 74.1M | 201.5M | (90.3M) | 86.7M | 99.7M | 104.7M | |
| Net Borrowings | 2.5M | 146.5M | (334.1M) | 605.9M | 696.7M | 731.6M | |
| Depreciation | 120.0M | 131.9M | 155.9M | 179.3M | 206.2M | 116.8M | |
| Change To Netincome | 98.1M | 98.9M | 107.6M | 66.3M | 76.2M | 79.2M | |
| End Period Cash Flow | 299.7M | 501.2M | 410.9M | 497.6M | 572.3M | 373.2M | |
| Free Cash Flow | 54.1M | (230.7M) | (277.7M) | (258.5M) | (232.6M) | (221.0M) | |
| Other Non Cash Items | 64.0M | 58.2M | 32.0M | 56.4M | 64.9M | 57.3M |
Jinhe Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jinhe Biotechnology's current stock value. Our valuation model uses many indicators to compare Jinhe Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jinhe Biotechnology competition to find correlations between indicators driving Jinhe Biotechnology's intrinsic value. More Info.Jinhe Biotechnology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.60 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Jinhe Biotechnology Co is roughly 1.66 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jinhe Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jinhe Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jinhe Biotechnology Systematic Risk
Jinhe Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jinhe Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Jinhe Biotechnology correlated with the market. If Beta is less than 0 Jinhe Biotechnology generally moves in the opposite direction as compared to the market. If Jinhe Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jinhe Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jinhe Biotechnology is generally in the same direction as the market. If Beta > 1 Jinhe Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Jinhe Biotechnology Co Total Assets Over Time
Jinhe Biotechnology Thematic Clasifications
Jinhe Biotechnology Co is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Jinhe Biotechnology March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jinhe Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jinhe Biotechnology Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jinhe Biotechnology Co based on widely used predictive technical indicators. In general, we focus on analyzing Jinhe Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jinhe Biotechnology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 14.51 | |||
| Value At Risk | (3.54) | |||
| Potential Upside | 3.05 |
Complementary Tools for Jinhe Stock analysis
When running Jinhe Biotechnology's price analysis, check to measure Jinhe Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jinhe Biotechnology is operating at the current time. Most of Jinhe Biotechnology's value examination focuses on studying past and present price action to predict the probability of Jinhe Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jinhe Biotechnology's price. Additionally, you may evaluate how the addition of Jinhe Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets |